Microbiota contribute to skin damage in cancer therapy
EGFR inhibitors such as erlotinib interrupt the growth of cancer cells and are approved to treat malignancies such as lung and colorectal cancer....
Pierre Fabre amends license agreement with Puma Biotechnology
According the extended agreement, Pierre Fabre may not only market the breast cancer recurrence blocker Nerlynx® (neratinib) within Europe and...
Researchers target ferroptosis resistance of cancer cells
In Nature, Sebastian Doll from Marcus Conrad's group at Helmholtz Center Munich and the group of José Pedro Friedmann Angel at University Würzburg,...
BIOncoTech Therapeutics and MSD combine cancer drugs
The clinical collaboration aims at providing clincial Phase II evidence that Bioncotech Therapeutics’ RNA–based cancer lead BO-112 can improve the...
Novo Holdings invest US$12m in AMR companies
Novo Holdings’ REPAIR Impact Fund has announced the funding of two companies totalling its investments into companies that fight antimicrobial...
Tecentriq-Avastin combo hits endpoint in liver cancer
Data from 501 treatment-native HCC patients enrolled in the open label IMbrave150 Phase III study demonstrated a incremental improvement...
AMR: ENABLE selects Mutabilis candidate
Efficacy of beta-lactam antibiotics, which represent 65% of the antibiotics sold throughout the world, is increasingly challenged in Gram-negative...